Application of vitamin D binding protein as marker in diagnosis of mental disease depression

Abstract

The invention discloses application of vitamin D binding protein as a marker in diagnosis of mental disease depression, and particularly relates to application of a reagent for detecting the content of the vitamin D binding protein in preparation of a reagent for diagnosing the mental disease depression. Differential expression of the vitamin D binding protein in plasma of schizophrenia, bipolar mania, depression and non-mental disease control persons is indicated, and the specificity of the vitamin D binding protein in plasma of depression patients is only improved; the protein is singly usedas a peripheral blood biomarker to detect the content of the protein and is used for diagnosing depression, so that the differential diagnosis accuracy of depression and healthy people or schizophrenia and bipolar mania of other mental diseases can be remarkably improved. Therefore, vitamin D binding protein content detection has high clinical application value in depression diagnosis, and a brand-new way is provided for rapid and effective diagnosis of mental disease depression.

Description

Technical field [0001] The invention belongs to the field of biological sciences, relates to the rapid and convenient specific differential diagnosis of mental diseases such as depression, and specifically relates to the application of vitamin D binding protein as a marker in the diagnosis of mental illness and depression. Background technique [0002] Depression, also known as melancholia, is a type of affective disorder characterized by depression. The WHO reports that depression will become the world's second-most disease in 2020 and will become the leading cause of death and disability by 2030. The current clinical diagnosis of depression and other mental diseases mainly refers to the "Chinese Classification and Diagnosis of Mental Disorders (Third Edition)" (CCMD-3), the United States' International Classification of Diseases Tenth Edition (ICD-10), and The Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) (DSM-IV) and the Diagnostic and Statistical Man...

AI Technical Summary

Problems solved by technology

The current clinical diagnosis of depression and other mental diseases mainly refers to "Chinese Classification and Diagnostic Criteria of Mental Disorders (Third Edition)" (CCMD-3), the United States' "International Classification of Diseases Tenth Edition" (ICD-10), " Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) and Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V), but the method itself suffers from a serious drawback: subjectivity Strong, poor diagnostic consistency and high misdiagnosis rate

Since the detection of VDB in the brain is almost difficult to achieve in vivo, and peripheral plasma is relatively easy to obtain, there is no use of VDB as a differential diagnosis between depression and other mental diseases (such as schizophrenia, bipolar mania, etc.) Biomarker Research

Images